Diagnostic Biochips unveiled a neural probe technology intended to add functional electrophysiological readouts to organoid screening, with the goal of improving early‑stage predictive validity and reducing late‑stage clinical failures. Brian Jamieson presented the approach as a way to capture activity‑based endpoints that molecular assays miss. Functional electrophysiology measures action potentials, synaptic events and network behavior — complementary signals to molecular biomarkers — and could refine target selection and candidate triage in neuroscience programs. If widely adopted, the platform could change preclinical screening workflows and de‑risk translational gaps that drive costly clinical attrition.